Inside Medicine with Private Medical

✓

Claim

Key Takeaways

• GLP-1 agonists target factors in the brain and gut that drive obesity in the first place
• GLP-1 agonists highlight that obesity isn’t just about behavioral change and individual responsibility, but there are biological mechanisms contributing to obesity
• Users tend to follow a significantly reduced meal schedule but it’s important to keep protein intake high and incorporate resistance training 2-3x per week (at least 30-minute sessions)
• The best results will still come from users who use GLP-1 agonists in combination with lifestyle modifications – this will also help with plateaus that will happen
• Tips to push through a plateau: exercise, self-monitoring behaviors (food tracking, weight monitoring), celebrate non-scale victories (increased energy, increased activity, etc.)

Read the full notes @ podcastnotes.org

Private Medical physicians Dr. Natalie Walsh and Dr. Tatiana Ivan. Dr. Michelle Cardel, an obesity and nutrition scientist, registered dietitian, and the Head of Clinical Research & Nutrition at WeightWatchers. In this interview, she uncovers misconceptions about weight loss, including the truth about GLP-1 inhibitors, most commonly known under brand names like Ozempic and Wegovy. She also discusses the science of lifestyle change, how to talk about weight and health with our children, and the challenges of weight maintenance. 

We hope this episode inspires you to think differently about your health and the healthcare system. Please subscribe to our feed and our bimonthly medical dispatch.